Publication | Open Access

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Patient-reported OutcomesMedicineCancer ManagementPathologyAlectinib Versus CrizotinibCancer TreatmentOncologyRadiation OncologyLung Cancer